Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia

Archives of Medical Research

Volumn 45, Issue 4, 2014, Pages 343-350

  Chávez González, Antonieta ^a   Dorantes Acosta, Elisa ^b   Moreno Lorenzana, Dafne ^a   Alvarado Moreno, Antonio ^c   Arriaga Pizano, Lourdes ^c   Mayani, Héctor ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b Federico Gomez Children's Hospital   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

CD117; CD123; CD90; CD96; Hematopoietic progenitor cells; Hematopoietic stem cells; Pediatric acute myeloid leukemia

Indexed keywords

CD123 ANTIGEN; CD34 ANTIGEN; CELL SURFACE MARKER; CYTARABINE; DOXORUBICIN; MEMBRANE ANTIGEN; MERCAPTOPURINE; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CELL POPULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRESCHOOL CHILD;

CD117; CD123; CD90; CD96; HEMATOPOIETIC PROGENITOR CELLS; HEMATOPOIETIC STEM CELLS; PEDIATRIC ACUTE MYELOID LEUKEMIA;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, THY-1; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 84901982076     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.04.001     Document Type: Article

References (35)

1. Estey E. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:90-99.
2. Liang D., Chang T., Lin K., et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006, 20:136-141.
3. Creutzig U., Zimmermann M., Ritter J., et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005, 19:2030-2042.
4. Smith F., Alonzo T., Gerbing R., et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005, 19:2054-2062.
5. Lie S., Abrahamson J., Clausen N., et al. Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia 2005, 19:2090-2100.
6. Ravindranath Y., Chang M., Steuber C., et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005, 19:2101-2116.
7. Hope K., Jin L., Dick J. Human acute myeloid leukemia stem cells. Arch Med Res 2003, 34:507-514.
8. Hope K., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743.
9. Warner J., Wang J., Hope K., et al. Concepts of human leukemic development. Oncogene 2004, 23:7164-7177.
10. Blair A., Hogge D., Ailles L., et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long term proliferative ability in vitro and in vivo. Blood 1997, 89:3104-3112.
11. Blair A., Sutherland H. Primitive acute myeloid leukemia cells with long term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000, 28:660-671.
12. Jordan C., Upchurch D., Szilvassy S., et al. The interleukin 3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
13. Guan Y., Hogge D.E. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia. Leukemia 2000, 14:2135-2141.
14. Terpstra W., Ploemacher R.E., Prins A., et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 1996, 88:1944-1950.
15. Mayani H., Flores-Figueroa E., Chavez-Gonzalez A. In vitro biology of human myeloid leukemia. Leuk Res 2009, 33:624-637.
16. Dorantes-Acosta E., Chavez-Gonzalez A., Santos J., et al. Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia. Pediatr Blood Cancer 2008, 51:741-746.
17. Montesinos J.J., Sanchez-Valle E., Flores-Figueroa E., et al. Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines. Leuk Lymph 2006, 47:1379-1386.
18. Manz M., Miyamoto T., Akashi K., et al. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 2002, 99:11872-11877.
19. Craig W., Kay R., Cutler R., et al. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993, 177:1331-1342.
20. Mayani H., Lansdorp P.M. Thy 1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 1994, 83:2410-2417.
21. Hosen N., Park C., Tatsumi N., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007, 104:11008-11013.
22. Chavez-Gonzalez A., Rosas-Cabral A., Vela-Ojeda J., et al. Severe functional alterations in vitro in CD34+ cell subpopulations from patients with chronic myeloid leukemia. Leukemia Res 2004, 28:639-647.
23. Wuchter C., Ratei R., Spahn G., et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001, 86:154-161.
24. Buccisano F., Rossi F.M., Venditti A., et al. CD90/Thy1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004, 125:203-212.
25. Kimura Y., Ding B., Imai N., et al. c-kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration for adult hematopoiesis. PLoS One 2011, 6:e26918.
26. Malaise M., Steinbach D., Corbacioglu S. Clinical implications of c-kit mutations in acute myelogenous leukemia. Curr Hematol Malign Rep 2009, 4:77-82.
27. Lauria F., Bagnara G.P., Rondelli D., et al. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia. Leukemia Lymph 1995, 18:451-455.
28. Buhring H.J., Ullrich A., Schaudt K., et al. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia 1991, 5:854-860.
29. Muñoz L., Nomdedéu J., López O., et al. Interleukin-3 receptor-α chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001, 86:1261-1269.
30. Rollins-Raval M., Pillai R., Warita K., et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol 2013, 21(3):212-217.
31. Testa U., Riccioni R., Militi E., et al. Elevated expression of IL3Ra in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis. Blood 2002, 100:2980-2988.
32. Vergez F., Green A., Tamburini J., et al. High levels of CD34+CD38low/-CD123+ blast are predictive an adverse outcome in acute myeloid leukemia: a groupe oust-este des leucemies aiguies et Maladies du Sang (GOELAMS) study. Haematologica 2011, 96:1792-1798.
33. Jin L., Lee E., Ramshaw H., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor a chain, eliminates human acute myeloid leukemia stem cells. Cell Stem Cell 2009, 5:31-42.
34. Van Rhenen A., van Dongen G.A.M.S., Kelder A., et al. The novel stem cell-associated antigen CLL1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
35. Van Rhenen A., Moshaver B., Kelder A., et al. Aberrant marker expression patterns on the CD34+ CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007, 21:1700-1707.